14
May

06:00 PM CEST

Drug Discovery Biology & Bioinformatics Strategy Dinner

Season 52, 3535 US-1 Suite 100B Princeton, NJ 08540

FULLY BOOKED

What to expect

Timely information, interactive format

Join us for dinner, drinks and discussions on how technology is shaping the future of Drug Discovery Biology

Curia is a leading intellectual property and solutions development company serving the pharmaceutical industry from early discovery through chemical development and manufacturing of API and drug product. Curia discovery expertise, technologies and solutions are widely employed by industry, non-profits and Federal government discovery, development and manufacturing programs.

Engage in conversation with peers and Curia experts in understanding how technology is impacting drug discovery. Hear of recent research results highlighting what your peers are doing with technology and how it is helping drive new levels of insight and efficiency.

Curia, from Curiosity to Cure

Our Agenda

Why you should attend

At Curia the journey to medical breakthrough may be linear, but it’s never simple. From discovery through manufacturing, launch through commercialization, we leverage deep scientific expertise and state-of-the-art technology to ensure every stage of this intricate process advances as quickly and accurately as possible.

Meet Our Facilitator

Christopher Conway

President, Research and Development Curia

Chris is a seasoned business executive with a 25 year strong track record across a variety of industry verticals including aerospace, pharmaceutical/biotech and contract research, development, and manufacturing. Chris is highly experienced in P&L leadership, sales, and marketing having worked in large and small, public and private equity backed companies. Currently, Chris serves as President and R&D Business Unit Head at Curia, a global top ten organization in contract research, development and manufacturing services, serving the pharmaceutical/biotech industry. Chris also currently serves as a Director on the board of two Life Sciences organizations including Viyash Life Sciences Private Limited, a Carlyle owned company, as well as the Drug, Chemical & Associated Technologies Association, Inc. (DCAT). Chris received his B.S. in Marketing & Management from Siena College and his Doctorate of Humane Letters from the Albany College of Pharmacy and Health Sciences

Dr. Grant Carr

Vice President, Head of Global R&D Drug Discovery Curia

Douglas Kitchen

Research Fellow, Medicinal Chemistry Curia

Jim LaRocque

Senior Research Scientist III, Assay Development & Screening Curia

James LaRocque, Senior Research Scientist III, is leading a team of Curia’s biologists focused on providing state of the art screening and compound characterization platforms, including high content screening and cellular imaging analysis along with traditional cellular and biochemical technologies and label free screening by mass spectrometry detection as part of Curia’s integrated drug discovery center in Buffalo, NY. Previously he focused on the development and implementation of screening platform technologies and led characterization initiatives to identify selective inhibitors of critical Ubiquitin pathway enzymes. He led efforts in assay development, compound management, screening and hit characterization on hundreds of exploratory projects for Wyeth over his 20 year career which started with antiviral research and later diversified in to a wide variety of therapeutic areas while contributing to Wyeth’s and later Pfizer’s lead identification programs.

Matthew Surman

Associate Director, Medicinal Chemistry Curia

Matt Surman, Ph.D. is Associate Director of Medicinal Chemistry at Curia Global and has over 20 years of industry experience. He joined the Curia Medicinal Chemistry department in 2002 and worked on contract research projects spanning a variety of therapeutic areas including oncology, anti-infectives and CNS disorders. From 2005 to 2011, he was part of the Curia internal Discovery Research and Development department. His efforts were focused in the area of metabolic disorders, particularly in obesity. He served as the project leader for the Curia MCH-1 antagonist program from 2008 until returning to the Medicinal Chemistry department in late 2011. During that time, the project culminated in the discovery and development of a successful Phase I clinical candidate. Since returning to the Medicinal Chemistry department, Dr. Surman has led the discovery efforts on a number of programs including projects involved in oncology, neurological disease, and pain. Multiple pre-clinical and clinical candidates have arisen from these efforts. Dr. Surman has over 40 peer reviewed publications and patent applications

More about Curia

More information

Curia is a Contract Research, Development and Manufacturing Organization with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecules offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state of the art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com

Further Information

Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch

Here To Help

Need help registering your team? Just get in touch and a member of the team will be happy to help.

14 May 2024

Drug Discovery Biology & Bioinformatics Strategy Meeting East Coast USA 2024

21 May 2024

Drug Discovery Biology & Bioinformatics Strategy Meeting West Coast USA 2024

16 May 2024

Clinical Operations and Clinical Trial Supply Chain Strategy Meeting East Coast USA 2024

23 May 2024

Clinical Operations and Clinical Trial Supply Chain Strategy Meeting West Coast USA 2024

15 May 2024

Medicinal Chemistry Strategy Meeting East Coast USA 2024

22 May 2024

Medicinal Chemistry Strategy Meeting West Coast USA 2024

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Curia

Curia – Drug Discovery Biology & Bioinformatics Strategy Dinner

Drug Discovery Biology & Bioinformatics Strategy Dinner

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%2012%2016'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Season 52, 3535 US-1 Suite 100B Princeton, NJ 08540

Timely information, interactive format

Our Agenda

Registration & Networking With a Signature Cocktail on Arrival

Roundtable Discussion Artificial intelligence and machine learning

Roundtable Discussion Glues & PROTACs, the next frontier?

Dinner

Closing Remarks and Coffee Dessert Cognac Closing

Why you should attend

Meet Our Facilitator

Christopher Conway

Dr. Grant Carr

Douglas Kitchen

Jim LaRocque

Matthew Surman

More about Curia

Further Information

Here To Help

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

0-10

10-50

50-100

14
May
2024

21
May
2024

16
May
2024

23
May
2024

15
May
2024

22
May
2024

Season 52, 3535 US-1 Suite 100B Princeton, NJ 08540